Expert Review of Precision Medicine and Drug Development最新文献_第8页

Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer 指导干预的无创生物标志物：前列腺癌症患者个性化管理

IF 1.2

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-08-03 DOI: 10.1080/23808993.2020.1804866

M. Frantzi, E. Gómez-Gómez, H. Mischak

{"title":"Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer","authors":"M. Frantzi, E. Gómez-Gómez, H. Mischak","doi":"10.1080/23808993.2020.1804866","DOIUrl":"https://doi.org/10.1080/23808993.2020.1804866","url":null,"abstract":"ABSTRACT Introduction Prostate cancer (PCa) is one of the most frequently diagnosed malignancies worldwide and is associated with high mortality. Broad screening through prostate-specific antigen analysis, along with an aging and growing population has resulted in a vast increase in PCa incidence. As not all PCa forms are life threatening, personalized management is of paramount importance to preserve survival and quality of life for the diagnosed patients. Owing to the complexity of PCa, noninvasive biomarkers for diagnosis, stratification and monitoring, are essential to tailor intervention among patients with different disease manifestations. Areas covered In this article, we aim to provide a critical assessment of the reported noninvasive biomarkers for PCa and their applicability according to the targeted clinical context. For this purpose, a systematic review of the literature published within the last five years was performed, focusing on noninvasive biomarkers to guide initial and repeated biopsies, stratify for active surveillance, monitor biochemical recurrence and metastasis, and adjust treatment for metastatic castration resistant PCa. Expert’s opinion Evidence from clinical trials on novel drugs and latest technological advancements, indicate several clinical applications for biomarkers to tailor intervention throughout PCa progression, toward a more personalized medicine approach in PCa clinical management.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"383 - 400"},"PeriodicalIF":1.2,"publicationDate":"2020-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1804866","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43225406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

A wide perspective of targeted therapies for precision medicine in autoimmune diseases 精准医学靶向治疗自身免疫性疾病的广阔前景

IF 1.2

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-07-31 DOI: 10.1080/23808993.2020.1804867

I. Miyagawa, S. Kubo, Yoshiya Tanaka

{"title":"A wide perspective of targeted therapies for precision medicine in autoimmune diseases","authors":"I. Miyagawa, S. Kubo, Yoshiya Tanaka","doi":"10.1080/23808993.2020.1804867","DOIUrl":"https://doi.org/10.1080/23808993.2020.1804867","url":null,"abstract":"ABSTRACT Introduction The strategy of precision medicine is achieved by the stratification of patients and targeted therapy. It has been shown that the pathological conditions of patients who are classified or diagnosed with a single disease are actually diverse in almost all autoimmune diseases. Therefore, the practice of precision medicine is important for the treatment of patients with autoimmune diseases. Areas covered At present, precision medicine has not been achieved in any autoimmune disease. This article reviewed the attempted use of precision medicine for the treatment of systemic lupus erythematosus and psoriatic arthritis. Expert opinion Although multiple molecular-targeted therapies are available for the treatment of rheumatoid arthritis, the response to each treatment strategy often differs markedly among patients, and it is unclear how they are differentially selected for each patient. The establishment of precision medicine is especially important in heterogenous autoimmune diseases (e.g., systemic lupus erythematosus, psoriatic arthritis). Various symptoms must be improved at the same time, but the treatment options are limited. Therefore, the selection of the optimal treatment for individual patients is complex. Although some predictors of the treatment response are reported, precision medicine has not been sufficiently well evaluated in real clinical practice, especially for autoimmune diseases.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"447 - 453"},"PeriodicalIF":1.2,"publicationDate":"2020-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1804867","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46728653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation Ivosidenib治疗IDH1突变的复发或难治性急性髓系白血病

IF 1.2

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-07-28 DOI: 10.1080/23808993.2020.1792286

F. Pasquier, C. Chahine, C. Marzac, S. de Botton

{"title":"Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation","authors":"F. Pasquier, C. Chahine, C. Marzac, S. de Botton","doi":"10.1080/23808993.2020.1792286","DOIUrl":"https://doi.org/10.1080/23808993.2020.1792286","url":null,"abstract":"ABSTRACT Introduction Management of acute myeloid leukemia (AML) remains challenging, especially for relapsed or refractory (R/R) AML patients who display poor prognosis with conventional therapies. This underlined the need for new treatments in this population. Areas covered This review will focus on ivosidenib, an oral inhibitor of mutated isocitrate dehydrogenase 1 (IDH1) enzyme. Mechanisms of IDH1 mutations and their inhibition by ivosidenib will be cover, as well as clinical efficacy and safety of ivosidenib in R/R AML. Ivosidenib has been approved by the FDA for R/R AML patients with IDH1 mutation in July 2018 and for unfit AML patients with IDH1 mutation as first line treatment in May 2019. Expert commentary Ivosidenib induces impressive response rates in R/R AML, a population of bad prognosis. Nevertheless, primary and acquired resistances to ivosidenib have been recently described, underlining importance of the ongoing clinical trials with ivosidenib in combination with standard chemotherapy, hypomethylating agents or other targeted therapies.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"429 - 438"},"PeriodicalIF":1.2,"publicationDate":"2020-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1792286","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43294350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Deep sequencing as an approach to understanding the complexity and improving the treatment of multiple myeloma 深度测序作为了解复杂性和改善多发性骨髓瘤治疗的一种方法

IF 1.2

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-07-16 DOI: 10.1080/23808993.2020.1792285

Louis Williams, J. Caro, B. Razzo, E. Boyle, G. Morgan

{"title":"Deep sequencing as an approach to understanding the complexity and improving the treatment of multiple myeloma","authors":"Louis Williams, J. Caro, B. Razzo, E. Boyle, G. Morgan","doi":"10.1080/23808993.2020.1792285","DOIUrl":"https://doi.org/10.1080/23808993.2020.1792285","url":null,"abstract":"ABSTRACT Introduction Multiple myeloma (MM) is plasma cell dyscrasia with marked variability in its clinical presentation and outcome, both of which are dictated by its underlying genetics. Next-generation sequencing techniques (NGS) have become essential to understanding the genomics of multiple myeloma. The exploitation of these advances in the clinic will require new clinical trial designs with endpoints that facilitate rapid readouts of success or failure and capture the impact of rare mutational events on outcomes. An understanding of NGS and its applications in multiple myeloma is therefore significant for both researchers and clinicians alike. Areas covered In this review, we summarize the significant advances that NGS has yielded in our understanding of the prognosis, clonal evolution, treatment and response assessment of multiple myeloma and its precursor conditions. We synthesize the relevant literature related to both genomics and the clinical management of MM, with articles selected based on our experience in the field. Expert opinion In the opinion of these authors, NGS will play a significant role in the future of precision medicine in multiple myeloma, especially as disease-specific panels and response adapted approaches to therapy gain traction. In the process, challenges related to cost, quality control, and standardization will need to be overcome.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"363 - 370"},"PeriodicalIF":1.2,"publicationDate":"2020-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1792285","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49370900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pharmacogenetics of tacrolimus and its implications for personalized therapy in kidney transplant recipients 他克莫司的药物遗传学及其对肾移植受者个体化治疗的意义

IF 1.2

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-06-19 DOI: 10.1080/23808993.2020.1776107

M. Francke, B. D. de Winter, L. Elens, N. Lloberas, D. Hesselink

引用次数: 4

Treating central nervous system lymphoma in the era of precision medicine 精准医学时代治疗中枢神经系统淋巴瘤

IF 1.2

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-06-16 DOI: 10.1080/23808993.2020.1777853

Y. Garcilazo-Reyes, M. Ibañez-Juliá, I. Hernández-Verdin, L. Nguyen-Them, N. Younan, C. Houillier, K. Hoang-Xuan, A. Alentorn

{"title":"Treating central nervous system lymphoma in the era of precision medicine","authors":"Y. Garcilazo-Reyes, M. Ibañez-Juliá, I. Hernández-Verdin, L. Nguyen-Them, N. Younan, C. Houillier, K. Hoang-Xuan, A. Alentorn","doi":"10.1080/23808993.2020.1777853","DOIUrl":"https://doi.org/10.1080/23808993.2020.1777853","url":null,"abstract":"ABSTRACT Introduction Primary central nervous system lymphoma (PCNSL) is a rare extra-nodal non-Hodgkin lymphoma that in the vast majority of cases belongs to diffuse large B-cell lymphoma (DLBCL) histology. The standard first-line treatment is based on high-dose methotrexate (HD-MTX) regimens. However, the majority of patients will relapse, leading to a poor prognosis of the disease. Areas covered Reviewed are the potential new therapeutic approaches in PCNSL. With the advent of tailored treatment, immunomodulators and immunotherapies are appearing as new promising therapeutic approaches for this orphan disease. This review seeks to summarize the novel approaches currently under evaluation. Expert opinion The therapeutic management of PCNSL is rapidly evolving with the description of PCNSL molecular alterations. However, due to the rarity of this disease, phase III clinical trials using new therapeutic drugs are still lacking. In addition, the vast majority of newly diagnosed PCNSL affect elderly patients, and specific and adapted clinical trials for this fragile population are warranted. Currently, the use of targeted therapies or immune-mediated treatments is only studied in relapsed/refractory (R/R) PCNSL, but the use of these approaches as a first-line treatment (compared with HD-MTX) could also be used as new promising approaches to decrease the toxicity associated with MTX regimens.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"275 - 281"},"PeriodicalIF":1.2,"publicationDate":"2020-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1777853","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44387843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities 精准医学治疗慢性丙型肝炎感染的前景:挑战与机遇

IF 1.2

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-06-09 DOI: 10.1080/23808993.2020.1764346

M. Frías, A. Rivero-Juarez, I. Machuca, Á. Camacho, A. Rivero

引用次数: 0

Phenotyping severe asthma: a rationale for biologic therapy 表型严重哮喘:生物治疗的基本原理

IF 1.2

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-06-07 DOI: 10.1080/23808993.2020.1776106

A. Vatrella, A. Maglio, S. Pellegrino, C. Pelaia, C. Stellato, G. Pelaia, C. Vitale

{"title":"Phenotyping severe asthma: a rationale for biologic therapy","authors":"A. Vatrella, A. Maglio, S. Pellegrino, C. Pelaia, C. Stellato, G. Pelaia, C. Vitale","doi":"10.1080/23808993.2020.1776106","DOIUrl":"https://doi.org/10.1080/23808993.2020.1776106","url":null,"abstract":"ABSTRACT Introduction Asthma is a complex disease with heterogeneity in etiology, triggers, clinical characteristics and different responses to pharmacological therapies. Areas covered Patients with severe uncontrolled asthma constitute a relatively small percentage, ranging from 5 to 10% of all asthmatics. These patients can benefit from targeted biological therapies developed in recent years. In fact, a better understanding of the etiopathological mechanisms of different phenotypes and endotypes of severe asthma have led to the availability of innovative biological therapies, able to modify the natural history of the disease by targeting molecules involved in airway inflammation. Several phenotypes based on clinical and physiologic variables and on inflammatory markers have been reported. Expert opinion The priority is to define the molecular process underlying the disease. In this context the recognition of T2 and non T2 inflammatory pathways, so called molecular phenotypes, represents the most reliable approach to drive the use of novel biological therapies. For this purpose, several biomarkers have been validated for identifying severe asthma phenotypes and for guiding the choice of the most appropriate treatment. The purpose of this review is to discuss the current knowledge about the molecular phenotypes of severe asthma, as well as the rationale underlying the use of existing biological drugs.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"265 - 274"},"PeriodicalIF":1.2,"publicationDate":"2020-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1776106","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44896154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

The emerging role of precision medicine in the treatment of ovarian cancer 精准医疗在癌症治疗中的新作用

IF 1.2

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-06-05 DOI: 10.1080/23808993.2020.1777854

G. Santangelo, G. Caruso, I. Palaia, F. Tomao, G. Perniola, V. Di Donato, M. Fischetti, L. Muzii, P. Benedetti Panici

{"title":"The emerging role of precision medicine in the treatment of ovarian cancer","authors":"G. Santangelo, G. Caruso, I. Palaia, F. Tomao, G. Perniola, V. Di Donato, M. Fischetti, L. Muzii, P. Benedetti Panici","doi":"10.1080/23808993.2020.1777854","DOIUrl":"https://doi.org/10.1080/23808993.2020.1777854","url":null,"abstract":"ABSTRACT Introduction Ovarian cancer is the primary cause of gynecologic cancer death in women worldwide and it is generally diagnosed at an advanced stage. Although the current standard treatment based on extensive cytoreductive surgery and systemic chemotherapy results in a high complete remission rate, recurrences are extremely frequent and exhibit progressive chemotherapy resistance, thus posing a difficult clinical challenge. Areas covered In the era of precision medicine, the increasing knowledge of cancer genomics, proteomics, and immune milieu facilitated the development of new targeted therapies (e.g. antiangiogenic drugs, PARP inhibitors, immunotherapy, folate receptor inhibitors, growth factor signaling inhibitors), that could improve ovarian cancer paradigm of care. Expert opinion In this review article, we discuss recent advances in the management of ovarian cancer, highlighting the need for a modern, personalized, and multi-disciplinary approach and for new predictive biological markers that will allow to choose the best therapeutic option between chemotherapy, molecular targeted agents, and immunotherapy for each patient. In the future, modern combinations of targeted therapies will open new chances for ovarian cancer patients. The main goal is to turn an aggressive disease eventually into a manageable chronic condition.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"283 - 297"},"PeriodicalIF":1.2,"publicationDate":"2020-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1777854","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42610334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Prognostic models to help predict patient responses to intravesical immunotherapy 预测患者膀胱内免疫治疗反应的预后模型

IF 1.2

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-06-01 DOI: 10.1080/23808993.2020.1768845

E. Laukhtina, D. D’andrea, B. Pradère, D. Enikeev, M. Abufaraj, S. Shariat

{"title":"Prognostic models to help predict patient responses to intravesical immunotherapy","authors":"E. Laukhtina, D. D’andrea, B. Pradère, D. Enikeev, M. Abufaraj, S. Shariat","doi":"10.1080/23808993.2020.1768845","DOIUrl":"https://doi.org/10.1080/23808993.2020.1768845","url":null,"abstract":"ABSTRACT Introduction Approximately 30–60% of patients treated with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) eventually experience disease recurrence within 2 years. Parsimonious use of BCG and accurate identification of those patients who might benefit from this therapy is of paramount importance in order to avoid BCG wastage, improve patient counseling regarding alternative therapy, patient’s survival and quality of life. We summarized the current literature on predictive and prognostic models on intravesical BCG therapy for NMIBC. Areas covered Clinicopathologic features are the strongest predictors of BCG response. In addition, several tissue, serum and urinary biomarkers have been investigated. However, they have not been shown to be robust enough to be implemented in daily clinical routine. Therefore, genetic and epigenetic markers and features of the tumor microenvironment have been investigated. The relationship between Th1 and Th2 microenvironments, as well as its related serum and urine biomarkers, was shown to play an important role in prediction of response to BCG treatment. Expert opinion No single tumor biomarker has been shown to be robust enough to change clinical decision making. Discoveries in the genetic signature profile of bladder cancer and immunological pathways represent the new frontiers in biomarker discovery and possible improvement in patient selection in the era of personalized medicine.","PeriodicalId":12124,"journal":{"name":"Expert Review of Precision Medicine and Drug Development","volume":"5 1","pages":"243 - 251"},"PeriodicalIF":1.2,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23808993.2020.1768845","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41655368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1